Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

The purpose of this study is to investigate if AZD2066 can relieve the pain arising from painful diabetic neuropathy compared to placebo.

Inclusion Criteria:

• Provision of informed consent prior to any study specific procedures.
• Clinical diagnosis of painful diabetic neuropathy.
• non-fertile females

Exclusion Criteria:

• Other pain that may confound assessment of neuropathic pain.
• Ongoing significant peripheral arterial diseases, skin ulcers, or amputation in the lower extremities.
• History of psychotic disorders among first degree relatives.